Back to Journals » OncoTargets and Therapy » Volume 7

Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma

Authors Hu H, Pan Y, Li Y, Wang L, Wang R, Zhang Y, Li H, Ye T, Zhang Y, Luo X, Shao L, Sun Z, Cai D, Xu J, Lu Q, Deng Y, Shen L, Ji H, Sun Y, Chen H

Received 8 December 2013

Accepted for publication 23 April 2014

Published 13 August 2014 Volume 2014:7 Pages 1423—1437

DOI https://doi.org/10.2147/OTT.S58900

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Haichuan Hu,1,3 Yunjian Pan,1,3 Yuan Li,2,3 Lei Wang,1,3 Rui Wang,1,3 Yang Zhang,1,3 Hang Li,1,3 Ting Ye,1,3 Yiliang Zhang,1,3 Xiaoyang Luo,1,3 Longlong Shao,1,3 Zhengliang Sun,1,3 Deng Cai,1,3 Jie Xu,1,3 Qiong Lu,1,3 Youjia Deng,1,3 Lei Shen,2,3 Hongbin Ji,4 Yihua Sun,1,3,* Haiquan Chen1,3,*

1Department of Thoracic Surgery, 2Department of Pathology, Fudan University Cancer Center, Shanghai, People's Republic of China; 3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; 4Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Science, Chinese Academy of Science, Shanghai, People's Republic of China
 
*These authors contributed equally to this work

Abstract: Lung adenocarcinomas have diverse genetic and morphological backgrounds and are usually classified according to their distinct oncogenic mutations (or so-called driver mutations) and histological subtypes (the de novo classification proposed by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society [IASLC/ATS/ERS]). Although both these classifications are essential for personalized treatment, their integrated clinical effect remains unclear. Therefore, we analyzed 981 lung adenocarcinomas to detect the potential correlation and combined effect of oncogenic mutations and histological subtype on prognosis. Analysis for oncogenic mutations included the direct sequencing of EGFR, KRAS, HER2, BRAF, PIK3CA, ALK, and RET for oncogenic mutations/rearrangements, and a rereview of the IASLC/ATS/ERS classification was undertaken. Eligible tumors included 13 atypical adenomatous hyperplasia/adenocarcinoma in situ, 20 minimally invasive adenocarcinomas, 901 invasive adenocarcinomas, 44 invasive mucinous adenocarcinomas, and three other variants. The invasive mucinous adenocarcinomas had a lower prevalence of EGFR mutations but a higher prevalence of KRAS, ALK, and HER2 mutations than invasive adenocarcinomas. Smoking, a solid predominant pattern, and a mucinous component were independently associated with fewer EGFR mutations. The ALK rearrangements were more frequently observed in tumors with a minor mucinous component, while the KRAS mutations were more prevalent in smokers. In addition, 503 patients with stage I–IIIA tumors were analyzed for overall survival (OS) and relapse-free survival. The stage and histological pattern were independent predictors of relapse-free survival, and the pathological stage was the only independent predictor for the OS. Although patients with the EGFR mutations had better OS than those without the mutations, no oncogenic mutation was an independent predictor of survival. Oncogenic mutations were associated with the novel IASLC/ATS/ERS classification, which facilitates a morphology-based mutational analysis strategy. The combination of these two classifications might not increase the prognostic ability, but it provides essential information for personalized treatment.

Keywords: oncogenic mutation, IASLC/ATS/ERS classification, personalized treatment, molecular testing, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]